Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.56 |
| ▸ | RBP4 | P02753 | 2/20 | 0.54 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4546334 | 0.84 | TRPV1 (0.84) | TRPV1RXFP1HSD11B1RBP4MALT1 | |
| SCHEMBL1252470 | 0.81 | TRPV1 (0.66) | TRPV1HSD11B1RBP4MALT1KDM4E | |
| SCHEMBL3216080 | 0.76 | TRPV1 (0.69) | TRPV1HSD11B1RBP4EPHX2 | |
| SCHEMBL3932323 | 0.75 | TRPV1 (0.62) | TRPV1HSD11B1RBP4MALT1EPHX2 | |
| SCHEMBL4035778 | 0.75 | NPSR1 (0.70) | NPSR1EPHX2 | |
| SCHEMBL24424315 | 0.75 | EPHX2 (0.53) | TRPV1EPHX2CYP2C9 | |
| SCHEMBL1253240 | 0.75 | ALDH1A1 (0.59) | TRPV1HSD11B1RBP4MALT1KDM4E | |
| SCHEMBL12190505 | 0.74 | GAA (0.64) | TRPV1HSD11B1RBP4NPSR1 | |
| SCHEMBL1250860 | 0.74 | TRPV1 (0.78) | TRPV1HSD11B1RBP4MALT1 | |
| SCHEMBL12910238 | 0.73 | TRPV1 (0.76) | TRPV1RBP4MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168827-B2 | Amide derivative | AJINOMOTO CO., INC. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20090258900-A1 | AMIDE DERIVATIVE | AJINOMOTO CO. INC (JP) | 2009-10-15 | — | — | US | disclosed |
| US-7572815-B2 | Amide derivative | AJINOMOTO CO., INC. (JP) | 2009-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258900-A1 | AMIDE DERIVATIVE | NR0B1, NR0B2, NR1I3 | TRPV1 804/4885RXFP1 507/4885HSD11B1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.